ConductScience.org, home

Comparison · NCT04104646-sae

CHF6563 vs Morphine: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. CHF6563 vs Morphine: serious adverse events. Trial comparisons, record NCT04104646-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04104646-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.434wilson
Risk in group 2000.658wilson
Risk difference, group 1 minus group 20-0.6580.434newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1CHF6563
Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo~CHF6563: Sublingual CHF6563 administration at starting dose of 10 µg/kg q8~Morphine matched-placebo: Oral morphine-matched placebo administration
05EG000
Group 2Morphine
Oral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo.~Morphine: Oral morphine administration at starting dose of 0.07 mg/kg q4~CHF6563 matched-placebo: Sublingual CHF6563 matched-placebo administration
02EG001

Harm

What it counts
Total, serious adverse events
Time frame
AEs and serious AEs (SAEs) were collected from the time of informed consent signature or from the neonate's birth through treatment and follow-up (FU) period (48 h after last treatment). Daily phone calls with the primary caregiver was for the first 7 d; weekly phone contact was up to 6 weeks after the final opioid treatment dose. NOWS treatment duration depends on Finnegan Neonatal Abstinence Scoring Tool (FNAST) scores and differs for each neonate; the maximum length of treatment was 10 weeks.

Source ClinicalTrials.gov

Trial

Title
CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
NCT number
NCT04104646
Phases
PHASE2
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
CHF6563, Morphine, CHF6563 matched placebo, Morphine matched placebo
Lead sponsor
Chiesi Farmaceutici S.p.A.
Results first posted
2023-08-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04104646-sae